国内外医保药品目录管理模式比较  

Comparison of the Management Models of Domestic and Foreign Medical Insurance Covered Medicine Catalogs

作　　者：黄玉琼[1] 郭莺[1] 

机构地区：[1]复旦大学附属中山医院,上海200032

出　　处：《中国医疗保险》2013年第12期68-70,共3页China Health Insurance

摘　　要：澳大利亚、法国、英国等国家在制定医保药品目录过程中,引入药物经济学评价,关注价格与疗效的联系,同时鼓励使用普通药,并使之与支付政策相配套。我国医保药品目录制定由专家遴选、专家投票决定,缺少药物经济学评价。因此,我国应引入药物经济学评价、第三方监管及合理制定支付政策,减少片面追求进口药品、贵重药品的不合理需求。Australia, France, Britain and other countries introduced pharmacoeconomics evaluation when they created medicare medicine catalogs, and they concerned about the relationship between price and efficacy, as well as encouraged the use of generic medicines to match the payment policy. The medicare medicine catalog in China was formulated by the selection and vote of experts, which was lack of pharmacoeconomic evaluation. Therefore, China should introduce the pharmacoeconomic evaluation, the third party supervision which make payment policy rational to reduce the unreasonable demands of one-sided pursuit of imported drugs and precious drugs.

关 键 词：医保药品目录 现状比较 管理 

分 类 号：F841[经济管理—保险]